The effects of apomorphine (0.01 mg lkg SC) a direct acting dopamine (DA) agonist, MK-212 (6-chloro-2-{1-piperaziny/J-pyrazine) (20 mg PO), a direct-acting serotonin (5-HT) agonist, and placebo on smooth pursuit fYe movements were evaluated in 10 to 12 normal volunteers. Smooth pursuit was tested just prior to administration of either apomorphine, MK-212, or placebo (on separate days), and then repeatedly tested at 30 min intervals for two hours after dose administration. The smooth pursuit targets were a series of predictable, constant velocity ramps with velocities of 5° Isec (slow target) and 200lsec (fast target). Eye movements were recorded with infrared oculography, and the following six measures were obtained; steady-state gain (slow-target gain; fast-target-gain), corrective catch-up saccade (CUS) rate (slow-target-CUS-rate; fast-target-CUS-rate), and CUS amplitude (slow-target-CUS-amplitude; fast-target CUS-amplitude). The placebo test yielded a statistically significant monotonic decrease over time in slow-target gain and corresponding increase in slow-target-CUS-
ra te, but no effects of placebo were noted for the fast target. Apomorphine injection produced a marked reduction in both slow-target-gain and fast-target-gain at 30 min, returning to baseline thereafter. Apomorphine injection also produced a statistically significant increase in slow-target-CUS-amplitude. Ingestion of MK-212 produced a statistically significant increase in slow-target gain and fast-target-gain as well as a corresponding decrease in slow-target-CUS-rate and fast-target-CUS rate at 90 min or 120 min. There was evidence that the decline in slow-target-gain after apomorphine was associated with side-effects such as sleepiness, but the decline in fast-target-gain was not related to side-effects. The improved smooth pursuit performance after MK-212 was not related to side-effects. The data suggest that serotoninergic stimulation can improve smooth pursuit performance, whereas dopaminergic stimulation worsens this performance. [Neuropsychopharmacology 11:49-62, 1994] Although abnormal smooth pursuit eye-tracking is well documented in schizophrenia (Clementz and Sweeney 1990; Abel et al. 1992; Levy et al. 1993) , there are few studies addressing the possible neurochemical under pinning of this defIcit. Two neurotransmitters that have been implicated in the pathophysiology of schizo phrenia are dopamine (DA) and serotonin (5-HT) (Melt zer and Stahl 1976; Meltzer 1989; Davis et al. 1991) . Al though some studies have attempted to relate eye movement dysfunction to neurochemical mechanisms of schizophrenia (see discussion), few studies have used direct-acting agonists, or addressed the role of 5-HT.
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Neuroleptic drugs share in common the ability to block 02 OA receptors at clinically effective doses (Wiesel et al. 1990 ); thus, any effect produced by this chemically diverse class of drugs might indicate the ex istence of a tonic direct or indirect 02 OA receptor mediated influence on eye-tracking. The effect of chronic treatment with neuroleptic drugs on eye tracking in patients with schizophrenia has been re cently reviewed Lipton et al. 1983; Abel and Hertle 1988; Spohn et al, 1988) . No effect of typical neuroleptics has been documented. These re sults indicate that smooth pursuit eye-tracking in pa tients with schizophrenia is not sensitive to diminished 02 receptor stimulation. This does not eliminate the possibility that smooth pursuit is modulated by dopa minergic stimulation in normal subjects, or that en hanced dopaminergic activity may affect smooth pur suit. To our knowledge there are no published studies of the acute effects of neuroleptics or dopamine agonists on specifIc quantitative smooth pursuit measures in healthy normal subjects, or schizophrenic patients. 1 Thus, &rm documentation of the absence of an effect of 02 OA receptor blockade, or stimulation on smooth pursuit performance is lacking.
Evaluation of the potential role of neurotransmit ters in smooth pursuit by administering direct-acting agonists has considerable potential to clarify the regu lation of this important function. Apomorphine is a mixed 01 and 02 direct-acting OA agonist (Schechter and Greer 1987) that can stimulate both OA autorecep tors and postsynaptic receptors (Cooper et al. 1991) . Low doses are thought to preferentially stimulate au toreceptors (Meltzer 1981) , because these receptors are more sensitive to agonists (Cooper et al, 1991) . Auto receptor stimulation leads to a decrease in OA neuronal &ring, synthesis, and release (Meltzer 1982; Goldstein et al. 1990) . At higher doses, postsynaptic responses should predominate (Cooper et al. 1991) .
The role of 5-HT in smooth pursuit performance can also be addressed with a direct-acting agonist such as MK-212 (6-chloro-2[1-piperazinyl]-pyrazine). This compound is an aryl piperazine that has the behavioral 1 There are two published reports on the acute effects of neurolep tics on eye-tracking performance, but the eye movement analysis methods employed in these two studies were crude and diff1cult to relate to current fIndings. Holzman et al, (1975) reported on the qualita tive effects ("normal" versus "deviant" tracking) and quantitative ef fects ("velocity arrests") of acute administration of chlorpromazine (0.67 or 1.33 mg/kg p.o.) on electro-oculogram (EOG) recordings of pendulum tracking, and noted no deviant recordings, and no increase in velocity arrests resulting from drug administration. Ando et al. (1986) reported that haloperidol, in a range of doses starting from 0.004-0.032 mg/kg (i. m.) produced ". . . disruptions in smooth pur suit (that) were characterized by eye l1xation accompanied by some saccadic movements" (pp 697-698).
NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.1 and chemical effects of a direct-acting 5-HT agoni st (Clineschmidt et al. 1977; Clineschmidt 1979) . Most of the evidence suggests that MK-212 acts via the 5-HT2A and 5-HT2C receptors, but there is evidence linking MK-212 to 5-HT1A and 5-HT2B receptors. It has affm ity for 5-HT1A, 5-HT2A, and 5-HT2C binding sites (Hoyer 1988; Roth et al. 1992) ; however, MK-212 has 25-fold greater affInity for the clonal 5-HT2C than the 5-HT2A receptor (Roth et al, 1992; Choudhary et al, 1993) . Also, some endocrine effects of MK-212 in rodents have been suggested to be mediated by 5-HT 2C receptor stimul a tion (King et al, 1989) . Furthermore, some effects ofMK-212 (e.g., reinforcement of &xed interval responding, are blocked by ketanserin, a 5-HT 2A/2C antagonist) (Mansbach and Barrett 1986) . However, there is evi dence that MK-212 may interact with the 5-HT1A recep tor. Thus, MK-212 markedly inhibits the &ring of raphe neurons (Yarbrough et al. 1984) , an effect it shares with 5-HT 1A agonists. The effects of MK-212 in man may be mediated by stimulation of 5-HT1A, 5-HT2A, or 5-HT2c receptors. Thus, the prolactin-stimulating effects ofMK-212 in man are blocked by pindolol, a beta-adrenergic antagonist with selective 5-HT 1A antagonist activity (Meltzer et al., unpublished data) and are also blocked by clozapine, a 5-HT2A/5-HT2C antagonist (Roth et al, 1992) . Finally, the 5-HT2B receptor is implicated by a study demonstrating that MK-212 causes a dose-depen dent contraction of rat fundus strips (Cline schmidt et al. 1985) .
A proper evaluation of the neurotransmitter regu lation of smooth pursuit also requires a sophisticated analysis of smooth pursuit performance. Because the function of the smooth pursuit system is to match eye velocity to target-velocity, the ratio of eye-velocity to target-velocity, (i.e. gain), is the key smooth pursuit measure. Perfect performance yields a gain of 1.0, whereas subjects who track more slowly than the tar get have gains less than 1.0. Gain is inversely related to target velocity and generally increases with target predictability (Levin et al, 1988) . When gain is less than 1.0, position error accumulates, because the eye falls behind the target. This position error is typically cor rected with a small CUS in the direction of the target. The nonlinear relationship between gain, CUS ampli tude, and CUS rate has been modeled by Friedman et al, (1991) . 2 The purpose of the present study was to test the effect of apomorphine and MK-212 on smooth pursuit gain, CUS rate, and CUS amplitude in normal volun teers.
MATERIALS AND METHODS

Subjects
Twelve normal volunteers (10 male and two female) were recruited by advertisement. They underwent a physical and neurological examination, as well as a number of standard laboratory tests to screen for med ical illness. Also, subjects with a past psychiatric his tory or a psychiatric history in frrst-degree relatives were excluded. The subjects were not taking any psychoac tive medications at the time of the study, and had been free of all medication for at least one week before the study. The mean age was 27.5 years ± 5.9 years SO. All subjects provided informed consent.
Experimental Procedure
All subjects underwent all drug conditions (placebo, apomorphine, MK-212). Each drug was administered on a separate day, with a minimum of 48 hours between studies. For each test day, the subjects fasted from 12:00
A.M. and through the morning study. They reported to the eye-tracking laboratory at 9:00 A.M. The baseline eye-tracking recording was initiated after completion of visual acuity and ocular dominance tests, and a se ries of questions regarding the subject's ophthalmologic history. The subjects then received one of the follow ing: (1) an injection of apomorphine (0.01 mg/kg SC) and a placebo tablet, (2) a placebo injection and a tablet of MK-212 (20 mg), or (3) a placebo injection and a placebo tablet. The drug to be given on a particular day was chosen randomly until each subject had been tested three times, once under each of the three drug condi tions. Both the subject and the eye-tracking personnel were blind to the drug administered on a given day. The eye-tracking test was repeated every 30 min for 2 hrs.
Pharmacokinetics
The pharmacokinetics of apomorphine (bolus SC in jection) in humans have been described by Gancher et al. (1989) . According to them, apomorphine is rapidly absorbed following subcutaneous injection, with peak plasma concentrations occurring 3 min following ad ministration. Apomorphine rapidly equilibrates be tween blood and brain due to its high lipid solubility. Concentrations are up to eight times higher in brain than plasma. Antiparkinsonian effects of apomorphine are observed within 7 min and last for up to 1 hr fol lowing injection (Gancher et al. 1989; Truelle et al. 1975) .
Peak plasma levels were noted 2 hours after a sin gle oral dose of MK-212 in man (Merck Sharpe and Dohme Pharmaceuticals Inc., personal communica tion). No pharmacokinetic studies or detailed metabolic studies of MK-212 in man have been published; how-ever, the time course of central effects of MK-212 have been reported. The stimulating effects of MK-212 on se rum cortisol and prolactin peaked between 90 min and 120 min (Lowy and Meltzer 1988) . The temperature elevating effects of MK-212 peaked at 118 min (Lee et ai. 1992) .
Smooth Pursuit Stimulus
For ten of the twelve subjects, the tracking target was a red HeiNe laser reflected off a computer-controlled mirror galvanometer, and projected on a 5-ft radius arc located 5-ft from the eyelid of the subject's dominant eye. Subjects were seated and the head was held frrmly in place in a headrest by chin and forehead straps. The galvanometer received its input from an ampli£Ier controller unit. The input to the galvanometer controller was an analog signal generated by a 01 A converter in an IBM PC-type computer. The £Irst target waveform was a set of 10 constant velocity (5° Isec) horizontal ramps (£Ive ramps to the left and £Ive to the right) with an excursion of ± 15°. There was a 2.5 second pause between each ramp. The second waveform presented was identical to the £Irst, except for velocity that was 20° Isec. For the frrst two subjects (subjects GU and MP), the target was a bright spot on a monitor, and only a 5° Isec velocity with ± 10° excursion was presented, as described by Friedman et ai. (1991) . The monitor and laser stimuli were identical in all remaining respects.
As described previously, two subjects were not tested at the 20° Isec target speed. An additional sub ject failed to complete the 20° I sec recording session un der the apomorphine condition. Thus 11 = 12 for all con ditions at 5° Isec, n = 10 for placebo and MK-212 conditions at 200/sec, and n = 9 for the apomorphine condition at 200/sec.
Eye Movement Recording
The recording and analysis methods have been de scribed in detail (Friedman et ai. 1991; Friedman et ai. 1992a; Friedman et aI., 1992b) . In brief, eye movements were recorded monocularly from the dominant eye with infrared oculography. The signal conditioning unit was operated in the &Iter-out position. The output was led to a 50-Hz notch &Iter and 5-pole Butterworth low pass &Iter at 125 Hz (3 dB). Target and eye position signals were digitally sampled at 400 samples per sec per chan nel (12 bit resolution) and stored on disk for offline anal ysis. Eye-velocity was obtained digitally, using the com putational method of Usui and Amidror (1982) with parameters n = 1.5, L = 0.5 (bandwidth OC-52.5 Hz).
Eye Movement Analysis
All eye movement records were scored blind to drug condition.
To prevent the possible contamination of our pur suit measures by blinks, these events were marked in teractively. Eye movement data from 150 msec before to 500 msec after each blink were omitted from the anal ysis. With infrared oculography, blinks appear as sharp, fast, bipolar waves or spikes.
Smooth pursuit recordings typically consist of straight-line segments interrupted by saccades. The start and end of these straight line smooth pursuit seg ments, between saccades, were marked interactively. To compute segment gain, a regression line (least squares) for the eye position data was computed, and the slope of this line was divided by the slope of the target position trace. The average gain was computed after removal of segments with pursuit gain with out lying or extreme gain values. Outliers were 1.5 times the interquartile range above the 75th percentile or be low the 25th percentile (Norusis 1988) . Gain averaged over time was calculated for each subject. For this, the sum of the product of gain and duration for each seg ment was divided by the summed durations of all seg ments (Friedman et al. 1991) . The interrater reliability of this method of scoring gain, as assessed by the in traclass correlation coefficient, was 0.89 (Friedman et al. 1992b) .
The detection and measurement of corrective catch up saccade (CUS) was a multi-step process. Because by defmition, saccades cannot occur during pursuit seg ments, the interval between consecutive segments was displayed, and the operator indicated if a CUS occurred. Because CUS compensate for the position error that ac cumulates during smooth pursuit, a CUS must have been preceded and followed by segments during which the subject was near the target, and the gain was clearly greater than O. CUS must always be in the direction of target movement. After CUS detection, the beginning and ending points of a CUS were determined automat ically according to the following algorithm: (1) scan the intersegment interval for the point of peak velocity; (2) fmd the starting point by moving backwards in time from the point of peak velocity to the frrst point at which the eye velocity was at or below the target velocity; and, (3) fmd the ending point by moving forward in time from the point of peak velocity to the frrst point at which the eye velocity was at or below target velocity. The difference between eye position at these two points was taken as a measure of saccade amplitude in degrees of visual angle. The number of CUS was divided by the tracking time to yield a measure of rate (CUS / sec).
Subjective Ratings of Side-Effects
Subjective ratings of side-effects were made after each eye movement measurement. The Stanford Sleepiness Scale (Hoddes et al. 1973 ) was used to assess sleepi ness.1t is a seven-point scale with descriptive anchors.
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Increasing scores are associated with increasing feel ings of sleepiness. In addition, nausea, dizziness, rest lessness, strangeness, and irritability were also rated with 11 point scales, with 0 indicating "not at all," and 10 indicating "very much."
Statistical Analysis
Nonparametric statistical tests were employed through out, because much of the data was nonnormally dis tributed. Also, these tests are generally more conser vative, and may be more appropriate with modest sample sizes. For each drug (placebo, apomorphine, MK-212), the drug effect was frrst tested with a Fried man Two-Way ANOVA by Ranks (Friedman test) . This test can be thought of as a non parametric repeated measures ANOVA (Siegel and Castell an 1988) . The test statistic is denoted Fr. Following a signifIcant Fr, post hoc comparisons between any postdrug time point (T30-T120) and the pre drug baseline (TO) were per formed using a procedure that controlled for such mul tiple, nonindependent comparisons (Siegel and Castel Ian 1988) . In several cases, the time response appeared to be either a monotonic increase or decrease. In such cases, the monotonic trend was tested with the non parametric Page Test for Ordered Alternatives ("Page Test") (Siegal and Castellan 1988) . To assess the strength of association or effect size of a signiflcant result, 112 (eta-squared) was computed with parametric tech niques (Tabachnick and Fidell 1989) . This measure can be conceptualized as the proportion of the variance in a dependent variable that is accounted for by a particu lar effect. As a further check on the result, Wilcoxon Signed Rank Tests were computed comparing ondrug data to placebo data for each time point for each smooth pursuit measure.
The effect of the drugs or placebo on side-effects was tested with a Wilcoxon Signed Rank Test. Correla tion analyses employed Spearman rank-order correla tion coefficients (rs). All p-values are two-tailed.
RESULTS
The Effects of Placebo on Smooth Pursuit Measures
The Friedman tests of the effect of placebo on the six smooth pursuit measures were all nonsigniflcant (Fig  ures la, Id, 2a, 2d , 3a, and 3d). However, there was a statistically signiflcant monotonic decrease in slow target-gain (Page test p < .05, Figure la , 112 for the lin ear trend = 0.28) and a statistically signifIcant mono tonic increase in slow-target-CUS-rate (Page test p < .05, Figure 2a , 11 2 for the linear trend = 0.23).
Individual slow-tar get-gain scores for each subject at baseline and at the time of peak effect of placebo (T120) are listed in Figure 1 . Effect of placebo, apomorphine or MK-212 on smooth pursuit gain. The data are plotted as mean ± standard error of the mean. Drugs or placebo were given after TO. (a) For placebo at SO/sec, there was a statistically signifIcant mono tonic decrease in gain over time (p < .05), but there were no signifIcant differences between any time points. (b) For apomor phine at SO/sec, note the sharp decline in gain 30 min after injection. Gain was signifIcantly reduced at T30 (*p < .01) and T60 (p< .05) compared to baseline (TO). (e) After MK-212, gain was signifIcantly elevated above baseline (TO) at T120 (p < .05).
(d) For placebo at 20° /sec, there was a small initial rise in gain followed by an even more gradual decrease, but no signifIcant diff erences between any time points was found. (e) For apomorphine at 200/sec, note the same sharp decline in gain at slow-target-gain was reduced in eight of the twelve sub jects.
The Effects of Apomorphine on Smooth Pursuit Measures
Apomorphine injection was followed by statistically signifIcant decreases in both slow-target-gain (Fr = 14.68, P = .005, Figure 1b ) and fast-target-gain (Fr = 17 .60, P = .002, Figure Ie) , as well as a statistically sig niftcant increase in slow-target-CUS-amplitude (Fr = 12 .78, P = .01, Figure 3b ). These effects of apomorphine were statistically significant at 30 min postinjection (all
2 for the decrease in slow-target-gain = 0.74, 112 for the decrease in fast-target-gain = 0.64, 11 2 for the increase in slow-target-CUS-amplitude = 0.47), and one effect (the decrease in slow-target-gain) was still sig niftcant at 60 min postinjection (p < .05). Thereafter, smooth pursuit performance graduall y returned to baseline (pre drug) levels. Although apomorphine ap peared to cause a marked increase in slow-target-CUS rate and fast-target-CUS-rate (Figures 2b and 2e) , there changes were only trends (p = .08, 0.11, respectively).
Individual gain scores for each subject at baseline and at the time of peak effect for apomorphine (T30 for both speeds) are listed in Table 1 . After apomorphine, slow-target-gain declined in all twelve subjects, and fast-target-gain declined in eight of nine subjects.
The Effects of MK-212 on Smooth Pursuit Measures
MK-212 ingestion was followed by statistically signifi cant increases in both slow-target-gain (Fr = 11.07, P = .03, Figure 1c ) and fast-target-gain (Fr = 9.84, P = .043, Figure 1f ), as well as a statistically significant decrease in fast-target-CUS-rate (Fr = 14 .00, P = .007, Figure  2£ ). Figure  1£ ) as well as statistically signibcant decreases in slow target-CUS-rate (p < .05,1 1 2 target-CUS-rate (p < .001, 112 = 0.80, Figure 2f ). MK-212 did not signibcantly affect CUS amplitude ( Figures  2b and 2e) . Individual gain scores for each subject at baseline and at the time of peak effect for MK-212 (T120 for the slow target, T90 for the fast target) are listed in Table  1 . After MK-212, gain increased in ten of twelve sub jects at SO/sec, and in eight of ten subjects at 20o/sec. Table 2 lists the signifIcance values for a series of Wil coxon Signed Rank tests comparing apomorphine or MK-212 with placebo at each time point. These results essentially confrrrn the Jindings of the within-drug comparisons described above. Apomorphine was associated with an early, marked reduction in gain, and an increase in CUS rate, and amplitude at both target speeds. MK-212 was associated with an increase in slow-target-gain, and a decrease in slow-target-CUS-rate and fast-target CUS-rate at T120.
Drug versus Placebo Comparisons
Correlations between Drug-Induced Changes in Gain and Baseline Gain
The decline (T120-TO) in slow-target-gain after placebo at time of peak effect (TI20) was correlated with the baseline slow-target-gain (rs = -0.66, P = .02). The preapomorphine baseline gain was not correlated with the change in gain at no (the time of peak effect) after apomorphine at either target speed. Similarly, there was no correlation between pre-MK-212 baseline gain and the peak change in gain after MK-212 (T120}3 at ei ther target speed. Figure 3 . Effect of placebo, apomorphine, or MK-212 on CUS amplitude. The data are plotted as mean ± standard error of the mean. Drugs or placebo were given after TO. SignifIcant effects occurred only for apomorphine at 5° /sec (b). In this case, CUS amplitude was signifIcantly elevated at T30 (p < .01) and T90 (p < . 05) .
Correlations between Apomorphine-Induced Changes in Gain and MK-212-Induced Changes in Gain
The effect of apomorphine on slow-target-gain at T30 and the effect of MK-212 on slow-target-gain at T120 were correlated as follows: at the slower target speed, the larger the effect (T30-TO) of apomorphine for a par ticular subject, the smaller the effect (T120-TO) of MK-212 for the same subject (rs = 0.67, P = .017). This rela tionship was not observed for fast-target-gain (rs = -0.28, p = .46). The effect size for apomorphine or MK-212 for sub jects GU and MP were intermediate and completely consistent with the group effects ( Table 1 ).
The Effects of Placebo, Apomorphine or MK-212 on Subjective Ratings of Side-Effects
The effects of placebo, apomorphine, or MK-212 on side-effects were tested at the time of peak effect for eye movement measures (T1203 for placebo and MK-3 The time of peak effect of MK-212 on slow-target-gain was T120 whereas the time of peak effect on fast-target-gain was T90. To mini mize the number of tests performed, T120 was chosen to evaluate the effect of MK-212 on side-effects. This is supported also by the evidence of a monotonic increase in gain over the entire 120 min period.
212, and T30 for apomorphine) ( Table 3 ). The Stanford Sleepiness Scale score was the most sensitive of all sub jective ratings to the effects of the drugs, or placebo. Thus, at the time of peak effect of placebo and apomor phine, subjects were significantly more sleepy (Table  3) . Also, at the time of peak effect of MK-212 there was a trend toward increased sleepiness (Table 3) . None of the other side-effect tests (nausea, dizziness, irritabil ity, strangeness) were statistically significant (Table 3) .
Correlations between Changes in Smooth Pursuit Gain and Changes in Subjective Ratings of Side-Effects
Correlations were computed relating changes in side effect measures with change in gain at the time of peak effect (T120 for slow-target-gain after placebo, no for slow-target-gain and fast-target-gain after apomor phine, T120 for slow-target-gain, and T90 for fast-target gain after MK-212) (Table 4) . Side-effect data were ana lyzed only for subjects with complete side-effect data (n = 9). After placebo or MK-212, there were no significant correlations between change in smooth pur suit gain at either target speed and change in subjec tive ratings of any side-effect. After apomorphine, change in slow-target-gain was signifIcantly inversely correlated with change in sleepiness, dizziness, and ir ritability at T30 (sleepiness: rs = -0.84, P = .005; diz- ziness: rs = -0.86, P = .003; irritability: rs = -0. 76, P = .018), but no correlations were signifIcant for fast target-gain (p-values range from .226 to .743).
DISCUSSION
The major fIndings of the present study were: (a) that slow-target-gain gradually declined Over a 2 hour period after placebo; (b) that slow-target-gain and fast-target gain declined sharply 30 min after apomorphine injec tion; (c) that slow-target-gain at 90 min and fast-target gain at 120 min were increased after and (d) that the effects of apomorphine and MK-212 on slow target-gain were inversely correlated. In general, these changes in gain were accompanied by compensating changes in corrective, CUS rate (placebo and MK-212), or CUS amplitude (apomorphine at 5° /sec). This is the frrst report of the effects of these agents on smooth pur suit gain and CUS. The placebo effects were presumably caused by the passage of time and repeated testing, rather than any effect of placebo per se. The gradual decline in slow target-gain and increase in slow-target-CUS-rate after placebo probably reflects the cumulative effects of fa- tigue. This is supported by the finding that subjects were signilicantly sleepier at T120 than at TO after placebo. Although fatigue is frequently cited as a poten tial cause of low gain (Leigh and Zee 1991), we are not aware of any previous study that clearly documented this effect. The decline in slow-target-gain was mild in magnitude (from 0.912 to 0.859 over 120 min). It is noteworthy, furthermore, that no decline was observed for fast-target-gain. If one accepts the hypothesis that the decline in slow-target-gain is caused by fatigue, the absence of an effect for the fast target suggests that fa tigue is less of a factor in tracking a substantially faster target. Other evidence, described below, is consistent with the hypothesis that performance when tracking a fast target is less susceptible to side-effects than when tracking a slow target. The susceptibility of slow-target performance to fatigue may simply reflect that this tar get is presented for a substantially longer period of time (82 sec) than the fast target (32.5 sec), because the same number of ramps are presented at both speeds. Per haps the slow target would, therefore, demand greater sustained vigilance than the fast target. Apomorphine led to a reduction in slow-target-gain and fast-target-gain 30 min postinjection. The reduc tion was marked and rapid (from .895 to 0.771 in 30 min for slow-target-gain and from 0.844 to 0.751 for fast target-gain). As mentioned previously, the pharma cokinetic data, as well as studies of motor effects in Par kinson patients, indicate that apomorphine can act within 10 min (Gancher et al. 1989; Truelle et al. 1975 ).
Further study is required to determine if the peak effect of apomorphine on gain occurs before 30 min. The de-NEUROPSYCHOPHARMACOLOGY 19 94-VOL. 11, NO.1 cline in slow-target-gain was associated with a signifi cant increase in corrective CDS amplitude, and there were trends toward increasing CDS rate at both target speeds.
Apomorphine also caused a statistically signifIcant increase in sleepiness at T30, an effect that is well documented (Meltzer 1982) . Furthermore, the effect of apomorphine on slow-target-gain was signifIcantly cor related (rs = -.84) with the effect on sleepiness. This pattern of results raises the possibility that the reduc tion in slow-target-gain after apomorphine was second ary to sedation. A number of compounds with sedat ing effects have been found to reduce smooth pursuit gain, including barbiturates (Padoan et al. 1992) , ben zodiazepines (Rothenberg and Selkoe 1981; Bittencourt et al. 1983; Padoan et al. 1992) , alcohol (Baloh et al. 1979; Barnes et al. 1984; Tedeschi et al. 1984; Stapleton et al. 1986 ), nitrous oxide (Magnusson et al. 1989) , and metha done (Rothenberg et al. 1980) . However, in an acute study of the effects of chlorpromazine on eye move ments, Holzman et al. (1975) found no effect on eye tracking in the presence of a large soporifIc effect. In the present study, the effect of apomorphine on fast target-gain was not related to increases in sleepiness (rs = -.26), even though the two gain effects were comparable in magnitude. It is possible that the reduced correlation between increased sleepiness and decreased gain during the fast target resulted from less statistical power (two fewer subjects), or a restriction of the range of gain changes. However, the magnitude of the corre lation was much less, suggesting that many more sub jects (89 subjects, assuming power = 0.8 and I-tailed alpha < 0.05) would be required to fInd a signifIcant rela tionship (Cohen 1988) . Also, the standard deviation of slow-target-gain change (0.078) was actually less than that of fast-target-gain change (0.083), indicating the absence of a "range restriction" limitation. Thus, the present evidence suggests that the effect of apomor- phine on fast-target-gain was not strongly related to the se dative effects of apomorphine. One explanation for this pattern of results is that the effect of apomorphine on gain is not secondary to sedation at either target speed. In further support of this notion, MK-212 also te nded to increase sleepiness (p = .068), but it was as sociated with an increase in gain. Nonetheless, the seda tive effect of apomorphine may well have contributed to the decline in slow-target-gain, especially if perfor mance when tracking the slow target is more suscepti ble to sedation, as suggested previously. Future studies employing levodopa for DA stimulation should help to clarify the role of sedation, because levodopa is as sociated with arousal (Bowen et al. 1975; Sassin 1975; Boivin and Montplasir 1991) .
If the effect of apomorphine is due to DA stimula tion at some point in the neural pathway controlling smooth pursuit, it would be of great interest to deter mine where this effect is mediated. The presence of sev eral types of DA receptors, including autoreceptors and postsynaptic receptors, complicates the interpretation. In the present study, we employed a standard "sub emetic," "nonsedating" dose of apomorphine (0.01 mg/ kg, or approximately 0.75 mg/person). Although this dose is frequently referred to as an "autoreceptor dose," the evidence supporting this classifIcation is scarce. Sev er al dose-response studies in animals have documented biphasic effects of apomorphine, and thus provide dosages for presynaptic and postsynaptic effects (Ljung berg and Ungerstedt 1976; Protais et a1. 1983; Stahle 1992) . However, we are aware of only one dose re sponse study in humans that addressed this issue: Lal et a1. (1989) recently reported that doses from 0.0035 to 0.005 mg/kg antagonized yawning, whereas doses above 0.007 stimulated yawning. Lal et al. (1989) con cluded that doses above 0.007 mg/kg stimulate post sy naptic receptors. This is consistent with the fInding that doses at or above 0.01 mg/kg reduce motor symp toms in Parkinson's disease (Duby et a1. 1972; Blin et al. 1990 ) -an effect that is presumably postsynaptic. On the other hand, evidence for a presynaptic effect was provided by Levy et al. (1984) , who reported a decrease in CSF levels of the DA metabolite homovanillic acid (HV A) in patients with schizophrenia, after a 0.75 mg/person dose. Considering that only one study has documented a biphasic response in humans (Lal et a1. 1989 ) and that reported results are not completely con sistent, caution precludes a frrm conclusion regarding autoreceptor versus postsynaptic receptor stimulation of the dose at this time.
Several studies have evaluated the role of catechol amines in smooth pursuit. Amphetamine increases syn aptic DA and norepinephrine (NE) by promoting re lease and blocking reuptake (Cooper et a1. 1991) . Most studies have not found an effect of amphetamine on smooth pursuit in normal controls (Tedeschi et al. 1983) Monoaminergic Effects on Smooth Pursuit 59 or psychiatric patients (Siever et a1. 1987; Bylsma and Pivik 1989) , although none of these studies measured gain or corrective saccades. Filip et a1. (1978) noted an improvement in smooth pursuit after amphetamine in normal volunteers, although the data analysis was idi osyncratic. Ando et a1. (1986) found that amphetamine disrupted eye-tracking in a dose-related manner in three monkeys; thus, no clear effect of amphetamine on eye tracking has been established. Furthermore, Tychsen and Sitaram (1989) reported no effect on smooth pur suit gain in normal controls after alpha-methyl para tyrosine, which blocks the synthesis of DA and NE. Also, Siever et a1. (1986) found no correlation between CSF levels of the DA metabolites HV A or dihydroxy phenylacetic acid and smooth pursuit. As previously mentioned, chronic neuroleptic treatment does not ap pear to affect smooth pursuit. These results do not con sistently implicate DA in smooth pursuit; however, these studies generally employed nonspecifIc smooth pursuit measures and indirect manipulations or mea sures of the DA system.
Several studies have reported low gain in Parkin son's disease (White et a1. 1983; Gibson et al. 1987) , which is associated with degeneration of the nigrostri atal DA system and marked DA depletion. In one re port, clinical improvement with chronic treatment of dopaminergic drugs was associated with an increase in gain (Gibson et al. 1987) , although Sharpe et al. (1987) did not fInd an increase in gain after levodopa treat ment in Parkinson's disease patients. This clinical evi dence suggests that low DA in the striatum is associated with low gain and is consistent with an apomorphine induced stimulation of DA autoreceptors on the nigro striatal DA neurons in the present study; however, neu rophysiological experiments have not implicated the nigrostriatal DA system in smooth pursuit function (Sharpe et a1. 1989) .
Thus, the extant literature does not provide strong support for or against a direct role of the DA system in the control of smooth pursuit; however, the evidence for a role of DA from the present study is based upon the application of a direct-acting agent and state-of-the art smooth pursuit assessment, accompanied by assess ment of subjective side-effects. ClarifIcation of the role of DA in smooth pursuit thus deserves further investi gation. Studies in normal subjects using specifIc, direct acting agents, and state-of-the-art assessments are likely to provide the most interpretable evidence.
In contrast to the reduction in gain after apomor phine, MK-212 was followed by an elevation of slow target-gain and fast-target-gain. The effect was delayed compared to the apomorphine effect probably as a re sult of the difference in the route of administration (PO versus SC). There were also statistically signifIcant monotonic decreases in CUS rate for both target speeds after MK-212. Indeed, the strongest effect of MK-212 on eye movements was the monotonic decrease in fast target-CUS-rate (p < .001). The finding that MK-212 can improve smooth pursuit performance in normal sub jects is surprising, especially because we are not aware of any other agent that has this effect. The increases in gain were not large (0.897 to 0.936 for slow-target gain, and 0.814 to 0.88 for fast-target-gain); however, the statistical analysis employed was conservative, and accounted for multiple, non-independent posthoc com parisons.
The increase in gain after MK-212 was probably un related to side-effects. First, there is no obvious a priori connection between improved smooth pursuit perfor mance and side-effects. Also, there was no significant effect of MK-212 on side-effects, although there was a trend toward increased sleepiness. Moreover, at the time of peak effect of MK-212 (T120), there were no statistically significant correlations between changes in side-effects and changes in gain. One correlation ap proached statistical significance, namely change in feel ings of strangeness (rs = -0.63, P = .067). It is unlikely that the effect of MK-212 on gain was mediated by feel ings of strangeness, however. Perhaps those subjects who felt most strange after MK-212 were more sensi tive to the central 5-HT stimulatory effect of this agent, and thus were more sensitive to effects on smooth pur suit gain.
To our knowledge, only one study has evaluated the effect of a 5-HT specific agent on smooth pursuit gain. Stott et al. (1989) studied the effect of ondanse tron, a 5-HT3 antagonist, on smooth pursuit in normal volunteers and found a small, but statistically significant reduction in gain; however, this effect of ondansetron may be related to effects on the OA system, because 5-HT3 antagonists have been shown to be extremely potent in antagonizing the behavioral consequences of increased mesolimbic OA activity (Costall et al. 1990 ). This notion assumes that increased mesolimbic OA is associated with increased gain. This would only follow if the gain reduction after apomorphine was mediated by OA autoreceptors, that similarly decrease OA re lease. The gain-elevating effect of MK-212 may also be related to effects on 5-HT3 receptors, because MK-212 also interacts with these receptors (Glennon et al. 1989) ; however, it is premature to speculate which type of 5-HT receptor is stimulated by MK-212. Specific antag onists of 5-HTlAl 5-HT2A, 5-HT2C, or even 5-HT3 recep tors will be needed for clarification.
The effects of 5-HT on the optokinetic slow phase response (that is similar to smooth pursuit) have been studied elegantly in the crab, Leptograpsus variegatus, by Erber and Sandeman (1989) . They found that sys temic and ocular injections of 5-HT increased optoki netic slow phase amplitude -a finding that is analogous to an increase in smooth pursuit gain.
It is of particular interest that the effects of apomor-NEUROPSYCHOPHARMACOLOGY 199 4-VOL. 11 , NO. 1 phine and MK-212 on slow-target-gain were inversely correlated. It is well established that serotonin can ex ert an inhibitory effect on the dopaminergic system (Korsgaard et al. 1985; Nash and Meltzer 1991) . As a specific relevant example, MK-212 has been shown to block apomorphine induced hypothermia (Menon and Vivonia 1981) ; thus, the ability of MK-212 to increase gain may be due to inhibition of a tonic inhibitory effect of OA neurons on gain. The fact that there was a significant correlation despite the obvious contributions of pharmacokinetic variability in absorption, metabo lism, and receptor dynamics of these agents, suggests that dopaminergic and serotoninergic mechanisms regulating gain are interconnected, either directly, or via an intermediary. If confirmed, the present results could lead to the development of a new method to study central seroto ninergic and dopaminergic mechanisms in man. Smooth pursuit performance may provide a nonhypothalami cally mediated, behaviorally-based measure for acute challenge studies. The effect of apomorphine and/or MK-212, as well as specific 01, 02, 5-HTIA, 5-HT2A, and 5-HT2C agonists on smooth pursuit could provide important new clues regarding receptor sensitivity in clinical populations, and on the effect of psychotropic drug treatment.
